<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01579201</url>
  </required_header>
  <id_info>
    <org_study_id>LoubertHMR2012/01</org_study_id>
    <nct_id>NCT01579201</nct_id>
  </id_info>
  <brief_title>ED90 Determination of Carbetocin for the Prevention of Uterine Atony in Women Undergoing an Elective Cesarean Delivery</brief_title>
  <official_title>ED90 Determination of Carbetocin for the Prevention of Postpartum Uterine Atony in Women Undergoing an Elective Cesarean Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maisonneuve-Rosemont Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Université de Montréal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maisonneuve-Rosemont Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine the effective dose of carbetocin which would
      prevent the occurrence of postpartum uterine atony in 90% of women undergoing an elective
      cesarean delivery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postpartum hemorrhage is a major cause of maternal morbidity and mortality worldwide.
      Carbetocin have been shown effective in the prevention of uterine atony, which is the leading
      cause of postpartum hemorrhage. The Society of Obstetricians and Gynecologists of Canada
      recommends a single 100 mcg dose of carbetocin after elective cesarean delivery to prevent
      postpartum hemorrhage. However, there is no clear data in the literature regarding the lowest
      effective dose of carbetocin that should be administered. The use of the minimum effective
      dose of carbetocin may reduce its side effects, including hypotension, tachycardia, nausea,
      vomiting and flushing.

      In this trial, healthy term pregnant women undergoing elective cesarean delivery under spinal
      anesthesia will be recruited. The effective dose of carbetocin that will prevent postpartum
      uterine atony in 90% of the women (ED90) will be determined using a biased coin design
      up-down sequential allocation method. The determination of the carbetocin ED90 will help the
      anesthesiologist regarding the optimal dose of carbetocin to administer after elective
      cesarean delivery to prevent uterine atony.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose of carbetocin which will prevent uterine atony in 90% of subjects</measure>
    <time_frame>5 minutes</time_frame>
    <description>The uterine tone will be assessed by the obstetrician by palpation 5 minutes after injection. The uterine tone will be judged either as satisfactory or unsatisfactory.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of side effects</measure>
    <time_frame>20 minutes</time_frame>
    <description>Any of these side effects will be noted in the first 20 minutes following injection of carbetocin: hypotension, tachycardia, nausea, vomiting, flushing, headache, feeling of warmth, tremor, metallic taste, abdominal pain, back pain, chest pain and others.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressors administered</measure>
    <time_frame>20 minutes</time_frame>
    <description>The total dose of vasopressors administered in the first 20 minutes following the administration of carbetocin will be noted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti nausea therapy</measure>
    <time_frame>20 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional uterotonic medication administered</measure>
    <time_frame>20 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional uterine massage</measure>
    <time_frame>20 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Postpartum Hemorrhage</condition>
  <condition>Uterine Atony</condition>
  <arm_group>
    <arm_group_label>Carbetocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbetocin</intervention_name>
    <description>First patient: 70 mcg. Following doses according to biased coin design up-down sequential allocation method, with increments or decrements of 10 mcg. An unsatisfactory uterine tone will lead to an increment while a satisfactory uterine tone will result in either a decrement or no change.</description>
    <arm_group_label>Carbetocin</arm_group_label>
    <other_name>Duratocin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy pregnant women (ASA I or II)

          -  Elective cesarean delivery

          -  Spinal anesthesia

          -  Term gestation (37 weeks and above)

        Exclusion Criteria:

          -  Multiple gestation

          -  Known coagulopathy

          -  Active labour

          -  Uterine fibroids

          -  Body mass index &gt; 45

          -  Emergency cesarean section

          -  General anesthesia

          -  Any contraindication to neuraxial anesthesia

          -  Cardiopathies

          -  Known allergies to carbetocin

          -  Patient refusal

          -  Placenta previa/Placenta accreta

          -  Hypertensive disease/Preeclampsia/Eclampsia

          -  Polyhydramnios

          -  Previous history of uterine atony or postpartum hemorrhage

          -  Renal or liver disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Loubert, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maisonneuve-Rosemont Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Loubert, MD, FRCPC</last_name>
    <phone>514.252.3426</phone>
    <email>loubertch@yahoo.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Louis-Philippe Fortier, MD, FRCPC</last_name>
    <phone>514.252.3426</phone>
    <email>lpfortier@mac.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maisonneuve-Rosemont Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Loubert, MD, FRCPC</last_name>
      <phone>514.252.3426</phone>
      <email>loubertch@yahoo.fr</email>
    </contact>
    <contact_backup>
      <last_name>Louis-Philippe Fortier, MD, FRCPC</last_name>
      <phone>514.252.3426</phone>
      <email>lpfortier@mac.com</email>
    </contact_backup>
    <investigator>
      <last_name>Christian Loubert, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Coursol-Provost, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louis-Philippe Fortier, MD, FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Drolet, MD, FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2012</study_first_submitted>
  <study_first_submitted_qc>April 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2012</study_first_posted>
  <last_update_submitted>February 12, 2013</last_update_submitted>
  <last_update_submitted_qc>February 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maisonneuve-Rosemont Hospital</investigator_affiliation>
    <investigator_full_name>Christian Loubert</investigator_full_name>
    <investigator_title>Christian Loubert, MD, FRCPC</investigator_title>
  </responsible_party>
  <keyword>Postpartum Hemorrhage</keyword>
  <keyword>Uterine Atony</keyword>
  <keyword>Obstetric Anesthesia</keyword>
  <keyword>Cesarean Section</keyword>
  <keyword>Carbetocin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Uterine Inertia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carbetocin</mesh_term>
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

